|Assessment Status||Rapid review complete|
|Indication||In combination with other antiretroviral agents (ARVs) for the treatment of adults and adolescents (≥12 years; body weight ≥35 kg) infected with human immunodeficiency virus (HIV) type 1|
|Rapid review commissioned||26/04/2016|
|Rapid review completed||26/04/2016|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.|
The HSE has approved reimbursement following confidential price negotiations.